CD47 and neoplasm: Future work will be extended to in vivo studies to evaluate tumor accumulation and therapeutic efficacy, such as using CD47-humanized mouse models bearing stably CD47-transfected RM-1 prostate cancer tumors (FRα+/PD-L1+).